The Biorise® technology, available in the portfolio from Aptalis Pharmaceutical Technologies, enables effective oral dosing of poorly water soluble compounds and improved bioavailability for readily permeable compounds (BCS Class II) resulting in a higher amount of absorbed drug at higher absorption rates, allowing for equivalent therapy at lower doses and long-term product stability.
We offer a flexible approach to the development process for our partners, with various entry points within the formulation development continuum to optimize the ‘risk to spend’ ratio and meet customized needs. Time savings and cost efficiencies are gained through use of a single manufacturing processing step and short processing times, optimizing cycle times and providing batch consistency.